Ablynx and Merck Serono extend nanobody deal
This article was originally published in Scrip
Executive Summary
Ablynx is to receive a further €10 million up front from Merck Serono after the two companies expanded their relationship and entered a second agreement, to co-discover and co-develop nanobodies against an inflammatory disease target.